Azyter 15 mg/ g Norvegia - norvegese - Statens legemiddelverk

azyter 15 mg/ g

laboratoires théa s.a.s - azitromycindihydrat - Øyedråper, oppløsning - 15 mg/ g

Lyrica 75 mg Norvegia - norvegese - Statens legemiddelverk

lyrica 75 mg

farmagon - pregabalin - kapsel, hard - 75 mg

Pulmozyme 1 mg/ ml Norvegia - norvegese - Statens legemiddelverk

pulmozyme 1 mg/ ml

roche norge as - dornase alfa - inhalasjonsvæske til nebulisator, oppløsning - 1 mg/ ml

Voltarol 11.6 mg/ g Norvegia - norvegese - Statens legemiddelverk

voltarol 11.6 mg/ g

haleon denmark aps - diklofenakdietylamin - gel - 11.6 mg/ g

Voltarol Forte 23.2 mg/ g Norvegia - norvegese - Statens legemiddelverk

voltarol forte 23.2 mg/ g

haleon denmark aps - diklofenakdietylamin - gel - 23.2 mg/ g

Voltaren 23.2 mg/ g Norvegia - norvegese - Statens legemiddelverk

voltaren 23.2 mg/ g

2care4 - diklofenakdietylamin - gel - 23.2 mg/ g

Takipril 20 mg/ ml Norvegia - norvegese - Statens legemiddelverk

takipril 20 mg/ ml

b. braun melsungen ag - prilokainhydroklorid - injeksjonsvæske, oppløsning - 20 mg/ ml

Ronapreve Unione Europea - norvegese - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 og 5.

Blincyto 38.5 mikrog Norvegia - norvegese - Statens legemiddelverk

blincyto 38.5 mikrog

orifarm as - blinatumomab - pulver til konsentrat og oppløsning til infusjonsvæske, oppløsning - 38.5 mikrog

Voraxaze Unione Europea - norvegese - EMA (European Medicines Agency)

voraxaze

serb sas - glucarpidase - metabolic side effects of drugs and substances - alle andre terapeutiske produkter - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.